LEADER 03319nam  2200685Ia 450 
001 9911107635103321
005 20251017110113.0
010   $a0-309-14231-8
010   $a1-282-27265-9
010   $a9786612272653
010   $a0-309-13125-1
035   $a(CKB)1000000000789198
035   $a(OCoLC)427878159
035   $a(CaPaEBR)ebrary10327027
035   $a(SSID)ssj0000096382
035   $a(PQKBManifestationID)11121580
035   $a(PQKBTitleCode)TC0000096382
035   $a(PQKBWorkID)10076939
035   $a(PQKB)10857566
035   $a(MiAaPQ)EBC3378514
035   $a(Au-PeEL)EBL3378514
035   $a(CaPaEBR)ebr10327027
035   $a(CaONFJC)MIL227265
035   $a(OCoLC)923280588
035   $a(DNLM)1518373
035   $a(EXLCZ)991000000000789198
100   $a20090819d2009      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aAccelerating the development of biomarkers for drug safety $eworkshop summary /$fSteve Olson, Sally Robinson and Robert Giffin, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$dc2009
215   $a1 online resource (99 p.) 
300   $aBibliographic Level Mode of Issuance: Monograph
311 08$a0-309-13124-3 
320   $aIncludes bibliographical references (p. 55-57).
327   $aOverview Of key issues -- Cardiac safety biomarkers -- Assessing and predicting kidney safety -- Biomarkers of acute idiosyncratic hepatocellular injury in clinical trials -- Future considerations.
330   $a"Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held  'Assessing and Accelerating Development of Biomarkers for Drug Safety,' a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development."--Publisher's website.
606   $aBiochemical markers$vCongresses
606   $aDrugs$xSafety measures$vCongresses
606   $aDrugs$xTesting$vCongresses
615  0$aBiochemical markers
615  0$aDrugs$xSafety measures
615  0$aDrugs$xTesting
676   $a616.075
701   $aGiffin$b Robert B$01920977
701   $aOlson$b Steve$f1956-$0488724
701   $aRobinson$b Sally$0620917
712 02$aNational Research Council (U.S.).$bPlanning Committee for Assessing and Accelerating the Development of Biomarkers for Drug Safety : a Workshop.
712 12$aAssessing and Accelerating the Development of Biomarkers for Drug Safety. Workshop$f(2008 :$eWashington, D.C.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9911107635103321
996   $aAccelerating the development of biomarkers for drug safety$94768312
997   $aUNINA